» 
Jarkko Kalliomäki

Jarkko Kalliomäki

MD, Clinical lead and CMO

Role in PharmNovo: Clinical lead and CMO

Born: 1959.

Education: M.D. with specialization in Rehabilitation Medicine and Pain Medicine. 

Ph.D. in physiology, Lund University.

Other current appointments: Senior Consultant Physician, part time, at different multidisciplinary pain and rehabilitation clinics in Stockholm (Sophiahemmet, ReAct Rehab, and PBM).

Work experience: Jarkko has over 30 years of experience in the pain field, including basic and clinical pain research, senior roles at several multidisciplinary pain clinics and 12 years of experience from the pharma industry as principal scientist and senior clinical research physician at AstraZeneca R&D Södertälje. working mainly with analgesic drug development. 

Holdings: None.

Read more about Jarkko here

Member of:

Latest news

View all
June 5, 2024

PharmNovo presenting at the Global Forum

On May 29–30, BioStock hosted the Global Forum. The event is the first of its kind, aimed at bringing together growth stage Nordic life science companies looking to expand into new markets and experts armed with a profound knowledge of how business is done across the globe.

Read more
March 21, 2024

Positive final Phase I results

The final results from the Phase I clinical for our neuropathic pain drug candidate PN6047, demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. The findings from the Phase I trial show that PN6047 is safe and well-tolerated at the doses tested, with no serious adverse events reported.

Read more
March 10, 2024

Meet Bengt von Mentzer, founder and Chief scientific advisor

Bengt von Mentzer founded PharmNovo 16 years ago, and today, his visionary approach and scientific process still drive the development of the groundbreaking compound PN6047. At the intersection of innovation and scientific leadership, Bengt von Mentzer is paving the way for how to reshape the landscape of chronic pain treatment.

Read more
January 30, 2024

NIDA funds studies

The US National Institute of Drug Abuse (NIDA) has funded a project investigating the drug candidate PN6047, a novel and highly selective Delta Opioid Receptor Agonist (DORA), represents a unique approach to addressing this medical challenge.

Read more